Bart Claes

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Medicine, Oncology, Pharmacology +13

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Tim Maughan, Richard Adams, Christopher G. Smith et al. · The Lancet · 2011 · 967 citations

Medicine, Oncology, Pharmacology +12

Thrombomodulin Mutations in Atypical Hemolytic–Uremic Syndrome

Mieke Delvaeye, Marina Noris, Astrid De Vriese et al. · New England Journal of Medicine · 2009 · 546 citations · Full text

Medicine, Genetics, Hematology +15

Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene

Wim Janssens, Roger Bouillon, Bart Claes et al. · Thorax · 2009 · 466 citations · Full text

Medicine, Molecular Medicine, Aging +16

PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

Hans Prenen, Jef De Schutter, Bart Jacobs et al. · Clinical Cancer Research · 2009 · 293 citations · Full text

Medicine, Oncology, Pharmacology +17